These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33041762)

  • 21. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
    Mela F; Marti M; Bido S; Cenci MA; Morari M
    Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Voehringer P; Ferger B
    J Neurochem; 2010 Jan; 112(2):444-52. PubMed ID: 19895663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
    Picconi B; Bagetta V; Ghiglieri V; Paillè V; Di Filippo M; Pendolino V; Tozzi A; Giampà C; Fusco FR; Sgobio C; Calabresi P
    Brain; 2011 Feb; 134(Pt 2):375-87. PubMed ID: 21183486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F; Millan MJ; Brocco M; Morari M
    Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes.
    Pagliaroli L; Fothi A; Nespoli E; Liko I; Veto B; Devay P; Szeri F; Hengerer B; Barta C; Aranyi T
    Cells; 2021 Jun; 10(6):. PubMed ID: 34207710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
    Maeda T; Nagata K; Yoshida Y
    Neurosci Lett; 2008 Mar; 433(3):255-8. PubMed ID: 18255227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
    Aristieta A; Ruiz-Ortega JA; Miguelez C; Morera-Herreras T; Ugedo L
    Neurobiol Dis; 2016 May; 89():88-100. PubMed ID: 26852950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
    Conti MM; Meadows SM; Melikhov-Sosin M; Lindenbach D; Hallmark J; Werner DF; Bishop C
    Neuropharmacology; 2016 Nov; 110(Pt A):125-134. PubMed ID: 27452719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
    Marin C; Bonastre M; Mengod G; Cortés R; Rodríguez-Oroz MC; Obeso JA
    Exp Neurol; 2013 Dec; 250():304-12. PubMed ID: 24140562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
    Martinez AA; Morgese MG; Pisanu A; Macheda T; Paquette MA; Seillier A; Cassano T; Carta AR; Giuffrida A
    Neurobiol Dis; 2015 Feb; 74():295-304. PubMed ID: 25486547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
    Bido S; Marti M; Morari M
    J Neurochem; 2011 Sep; 118(6):1043-55. PubMed ID: 21740438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson's Disease.
    Palafox-Sanchez V; Sosti V; Ramirez-García G; Kulisevsky J; Aguilera J; Limón ID
    Neurotox Res; 2019 Apr; 35(3):563-574. PubMed ID: 30645726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.
    Nishijima H; Arai A; Kimura T; Mori F; Yamada J; Migita K; Wakabayashi K; Baba M; Ueno S; Tomiyama M
    Neuropathology; 2013 Aug; 33(4):391-6. PubMed ID: 23241013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
    Gil SJ; Park CH; Lee JE; Minn YK; Koh HC
    Brain Res Bull; 2011 Feb; 84(2):151-6. PubMed ID: 21163338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.
    Buck K; Voehringer P; Ferger B
    Neuroscience; 2010 Mar; 166(2):355-8. PubMed ID: 20026252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.